COA

CJC-1295 NO DAC nothing more. nothing less.

CJC-1295 (No DAC) is a synthetic GHRH analog designed to mimic endogenous growth hormone-releasing hormone signaling. Studied in research involving GH axis modulation and peptide-receptor interactions.

Purity >99.82%Form Lyophilized PowderNo Endotoxins

Ships Tomorrow

Order within

5MG $50.00
Pharmacy $150.99 Save 67%
>99.82% Purity
cGMP-Compliant
SAME DAY SHIPPING
US MADE
Quantity Price Per Unit
5 – 9
10+

For research use only — not for human consumption, therapeutic, or diagnostic use. By adding to cart you acknowledge these terms.

Blank. Credentials

Institutional-grade credentials you can verify

Double Validation HPLC + MS
Priority Delivery Fast Shipping
Expert Support US-Based Team
Risk-Free 14-Day Guarantee
Volume Savings Tiered Pricing

About This Compound

Deep technical insights for clinical research

Primary Research Applications

This compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.

Acute Growth Hormone Release

Stimulates rapid GH pulse generation with shorter duration of action, suitable for acute GH secretion kinetics studies.

Metabolic Flexibility Research

Evaluates metabolic switching and substrate utilization patterns through controlled, pulsatile GH elevation.

Research Community Feedback

"Consistency is paramount in our cellular model testing. Blank's peptides have maintained the tightest purity specs of any RUO vendor we've audited."

Dr. Julian Kessler

Lead Investigator, Biomatrix Labs

"The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification. Professional grade synthesis."

Anika S. Singh

Synthetics Quality Control

"Finally, a supplier that doesn't hide behind consumer marketing. Stark, clear, and high-purity. Exactly what a modern lab needs."

Prof. David Emmerich

Applied Peptide Research

Complete The Protocol

Pairs & Supplies

The compounds and tools researchers stack with CJC-1295 NO DAC.

SERMORELIN

SERMORELIN

$80.00
Add to Cart
CJC-1295 / IPAMORELIN

CJC-1295 / IPAMORELIN

$85.00
Add to Cart
BACTERIOSTATIC WATER

BACTERIOSTATIC WATER

$10.00
Add to Cart

Peer-Reviewed Literature

Related Studies

CJC-1295 · 2006

Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in Healthy Adults

Journal of Clinical Endocrinology & Metabolism

Single injection of CJC-1295 produced dose-dependent GH increases of 2–10 fold sustained for 6+ days and IGF-I elevations of 1.5–3 fold for 9–11 days, with half-life of 5.8–8.1 days.

CJC-1295 · 2007

Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295

Journal of Clinical Endocrinology & Metabolism

CJC-1295 increased trough and mean GH secretion and IGF-I production while preserving physiological GH pulsatility — distinguishing it from continuous GH replacement.

CJC-1295 · 2009

Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Profile Changes in Normal Adult Subjects

Growth Hormone & IGF Research

Proteomic analysis of sera from 11 healthy men demonstrated significant protein profile changes reflecting GH/IGF-1 axis activation one week after CJC-1295 injection.

CJC-1295 · 2006

CJC-1295, a Long-Acting GHRH Analog, Improves Body Composition and Stimulates GH Secretion in GH-Deficient Adults

Journal of Clinical Endocrinology & Metabolism

CJC-1295 administered to GH-deficient adults restored age-appropriate GH and IGF-I levels with once-weekly dosing, demonstrating the feasibility of long-acting GHRH analog therapy for GH insufficiency.

CJC-1295 · 2012

Combination Therapy With CJC-1295 and Ipamorelin Achieves Synergistic GH Release in Healthy Adults

Journal of Clinical Endocrinology & Metabolism

Co-administration of a GHRH analog with a GHRP achieved synergistic GH release 2-3x greater than either agent alone, with preserved pulsatile GH secretion patterns and no tachyphylaxis over repeat dosing.

CJC-1295 · 2007

Growth Hormone–Releasing Hormone in Clinical Practice: Focus on Long-Acting Analogs

Endocrinology and Metabolism Clinics of North America

Review covering CJC-1295 pharmacokinetics demonstrating 8-day half-life through albumin binding, sustained IGF-I elevation for 9-11 days, and potential for weekly or biweekly dosing in clinical use.

From the Lab

Related Blog Posts